HomeBUSINESS
BUSINESS

With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
(Feb.8.2018)

By Reiji Anasako

As the Japanese SGLT2 inhibitor market starts to get on a growth track, competition in the crowded space is expected to heat up particularly among the top three products. First-in-class Suglat (ipragliflozin) is now closely trailed by Forxiga (dapagliflozin), with last-to-market Jardiance (empagliflozin) also gaining traction in the newly diagnosed patient segment ...
(LOG IN FOR FULL STORY)